Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Rating Increased to Hold at ValuEngine
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Thursday.
Separately, Zacks Investment Research downgraded shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Six investment analysts have rated the stock with a hold rating, Infinity Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $1.17.
Infinity Pharmaceuticals (NASDAQ:INFI) traded down 3.21% during mid-day trading on Thursday, hitting $1.51. The company had a trading volume of 624,934 shares. The stock has a market capitalization of $76.17 million, a PE ratio of 755.00 and a beta of 2.63. Infinity Pharmaceuticals has a 1-year low of $0.84 and a 1-year high of $3.84. The stock has a 50 day moving average price of $1.78 and a 200-day moving average price of $2.11.
Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $19.60 million. During the same period last year, the company earned ($0.82) earnings per share. The business’s revenue for the quarter was down 99.9% compared to the same quarter last year. On average, analysts forecast that Infinity Pharmaceuticals will post ($0.84) earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Infinity Pharmaceuticals by 27.7% in the first quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after buying an additional 1,021,128 shares during the period. Acadian Asset Management LLC raised its stake in shares of Infinity Pharmaceuticals by 689.0% in the first quarter. Acadian Asset Management LLC now owns 585,232 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 511,057 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Infinity Pharmaceuticals during the first quarter valued at about $1,588,000. Platinum Investment Management Ltd. raised its stake in shares of Infinity Pharmaceuticals by 62.6% in the first quarter. Platinum Investment Management Ltd. now owns 810,232 shares of the biotechnology company’s stock valued at $2,617,000 after buying an additional 312,000 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Infinity Pharmaceuticals by 4.8% in the first quarter. Wellington Management Group LLP now owns 4,565,947 shares of the biotechnology company’s stock valued at $14,748,000 after buying an additional 207,876 shares during the period. Institutional investors own 76.49% of the company’s stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.